Drug Treatment of Heart Failure in Children: Gaps and Opportunities

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2022 Jan 27

PMID 35084696

Authors

Molly Weisert

Jennifer A Su

JonDavid Menteer

Robert E Shaddy

Paul F Kantor

Affiliations

Soon will be listed here.

Abstract

Medical therapy for pediatric heart failure is based on a detailed mechanistic understanding of the underlying causes, which are diverse and unlike those encountered in most adult patients. Diuresis and improved perfusion are the immediate goals of care in the child with acute decompensated heart failure. Conversion to maintenance oral therapy for heart failure is based on the results of landmark studies in adults, as well as recent pediatric clinical trials and heart failure guidelines. There will continue to be an important role for newer drugs, some of which are in active trials in adults, and some of which are already approved for use in children. The need to plan for clinical trials in children during drug development for heart failure is emphasized.

Citing Articles

Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy.

Koubsky K Physiol Res. 2024; 73(S2):S597-S613.

PMID: 39589305 PMC: 11627266.

Epidemiology of paediatric chronic heart failure in Germany-A population-based analysis.

Bobrowski A, Klebs S, Alibone M, Bovy L, Hackl D, Fleck T ESC Heart Fail. 2024; 11(6):4371-4380.

PMID: 39225059 PMC: 11631234. DOI: 10.1002/ehf2.15043.

Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But….

Schranz D Paediatr Drugs. 2022; 24(6):567-571.

PMID: 35931946 PMC: 9592665. DOI: 10.1007/s40272-022-00524-z.

References

Grady K, Dracup K, Kennedy G, Moser D, Piano M, Stevenson L . Team management of patients with heart failure: A statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation. 2000; 102(19):2443-56. DOI: 10.1161/01.cir.102.19.2443. View

Stevenson L, Massie B, Francis G . Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998; 135(6 Pt 2 Su):S293-309. DOI: 10.1016/s0002-8703(98)70257-1. View

Chen S, Dykes J, McElhinney D, Gajarski R, Shin A, Hollander S . Haemodynamic profiles of children with end-stage heart failure. Eur Heart J. 2017; 38(38):2900-2909. DOI: 10.1093/eurheartj/ehx456. View

Kantor P, Lougheed J, Dancea A, McGillion M, Barbosa N, Chan C . Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2013; 29(12):1535-52. DOI: 10.1016/j.cjca.2013.08.008. View

Konstam M, Gheorghiade M, Burnett Jr J, Grinfeld L, Maggioni A, Swedberg K . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297(12):1319-31. DOI: 10.1001/jama.297.12.1319. View

Luo X, Jin Q, Wu Y . Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis. Pharmacol Res Perspect. 2020; 8(3):e00614. PMC: 7272393. DOI: 10.1002/prp2.614. View

Regen R, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes A . Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol. 2013; 34(6):1463-8. DOI: 10.1007/s00246-013-0671-y. View

Hollenberg S, Stevenson L, Ahmad T, Amin V, Bozkurt B, Butler J . 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019; 74(15):1966-2011. DOI: 10.1016/j.jacc.2019.08.001. View

Ahmad T, Miller P, McCullough M, Desai N, Riello R, Psotka M . Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail. 2019; 21(9):1064-1078. PMC: 6774302. DOI: 10.1002/ejhf.1557. View

10.

Mody B, Hasan Khan M, Zaid S, Ahn C, Lloji A, Aronow W . Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era. Am J Ther. 2020; 28(6):e621-e630. DOI: 10.1097/MJT.0000000000001260. View

11.

Bayram M, De Luca L, Massie M, Gheorghiade M . Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005; 96(6A):47G-58G. DOI: 10.1016/j.amjcard.2005.07.021. View

12.

Cuffe M, Califf R, Adams Jr K, Benza R, Bourge R, Colucci W . Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287(12):1541-7. DOI: 10.1001/jama.287.12.1541. View

13.

Orstavik O, Manfra O, Andressen K, Andersen G, Skomedal T, Osnes J . The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium. PLoS One. 2015; 10(3):e0115547. PMC: 4349697. DOI: 10.1371/journal.pone.0115547. View

14.

Takahashi R, Talukder M, Endoh M . Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol. 2000; 400(1):103-12. DOI: 10.1016/s0014-2999(00)00385-x. View

15.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D . Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. J Cardiovasc Pharmacol. 2020; 76(1):4-22. PMC: 7340234. DOI: 10.1097/FJC.0000000000000859. View

16.

Abdelbaser I, Mageed N, Elfayoumy S, Elgamal M, Elmorsy M, Taman H . The direct comparison of inhaled versus intravenous levosimendan in children with pulmonary hypertension undergoing on-cardiopulmonary bypass cardiac surgery: A randomized, controlled, non-inferiority study. J Clin Anesth. 2021; 71:110231. DOI: 10.1016/j.jclinane.2021.110231. View

17.

Mebazaa A, Nieminen M, Packer M, Cohen-Solal A, Kleber F, Pocock S . Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17):1883-91. DOI: 10.1001/jama.297.17.1883. View

18.

Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J . Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2014; 1(2):103-11. DOI: 10.1016/j.jchf.2012.12.004. View

19.

Silvetti S, Silvani P, Azzolini M, Dossi R, Landoni G, Zangrillo A . A systematic review on levosimendan in paediatric patients. Curr Vasc Pharmacol. 2014; 13(1):128-33. DOI: 10.2174/1570161112666141127163536. View

20.

Wang H, Luo Q, Li Y, Zhang L, Wu X, Yan F . Effect of Prophylactic Levosimendan on All-Cause Mortality in Pediatric Patients Undergoing Cardiac Surgery-An Updated Systematic Review and Meta-Analysis. Front Pediatr. 2020; 8:456. PMC: 7456871. DOI: 10.3389/fped.2020.00456. View